A new study looks at this area in order to provide evidence for key recommendations in the treatment of such patients.
Exclusive: Vertex founder Joshua Boger joins tiny Boston biotech as chair, ahead of mid-stage readout for dementia drug
Since ending a two-decade tenure as Vertex Pharmaceuticals’ CEO in 2009, Joshua Boger has had no lack of opportunities to jump on biotech boards. He’s